Trials Sponsors Conditions Drugs Pricing

Conditions

Hepatocellular Carcinoma

Keywords

liver cancer

Interventions

T138067 intravenousDrug

doxorubicin intravenousDrug

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

pathologic diagnosis of unresectable HCC
chemotherapy-naïve for HCC

Sponsors & Collaborators

Tularik
Industrylead

Study Sites (76)

University of Alabama

Birmingham, Alabama, 35294, United States

University of California at San Francisco

San Francisco, California, 94115, United States

VA Medical Center

Miami, Florida, 33125, United States

University of Miami

Miami, Florida, 33136, United States

H. Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States

Loyola University of Chicago

Maywood, Illinois, 60153, United States

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

MeSH Terms

Conditions

Carcinoma, HepatocellularLiver Neoplasms

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

Mohammad Hirmand, MD
Tularik
STUDY DIRECTOR

Study Design

Study Type: interventional
Phase: phase 2 3
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

March 31, 2003

First Posted

April 2, 2003

Study Start

March 2003

Date type not reported

This date has not been verified as actual or estimated.

Last Updated

June 24, 2005

Record last verified: 2004-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00057382
Data provider: ClinicalTrials.gov
Source updated: 2005-06-24
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:21:25 UTC

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Conditions

Keywords

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (76)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

You may not qualify if:

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Conditions

Keywords

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (76)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

You may not qualify if:

Locations